Biomedical literature, made navigable

Follow the entities shaping the evidence.

Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.

An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.

View all families

Organisations named as supporting, sponsoring, or funding research.

5,089 articles · 9,137 mentions Institutions

Universities, hospitals, research centres, networks, and public bodies.

11,350 articles · 22,378 mentions Drugs

Named medicines, compounds, vaccines, and pharmacological agents.

10,506 articles · 58,393 mentions Diseases

Named diseases, disorders, syndromes, injuries, and health conditions.

23,712 articles · 125,551 mentions Treatments

Clinical therapies and care approaches used to manage a condition.

7,227 articles · 16,644 mentions Interventions

Programmes, procedures, policies, and other actions being evaluated.

4,132 articles · 9,994 mentions Clinical instruments

Named questionnaires, scales, scores, indices, and other clinical outcome assessments.

945 articles · 1,957 mentions

29,499matching articles

244,054matching entity mentions

30popular entities listed

0%of mentions human-reviewed

Filter articles

Entity familyJournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

Matching articles

29,499 articles · page 144 of 2459

PO:05:147 Impact of hypocomplementemia on clinical outcomes in systemic lupus erythematosus treated with rituximab: a single-center experience

lupusscimed · abstract · 2026-03-01 · 19 matching annotations

97.6%

Systemic Lupus Erythematosus Rituximab SLE prednisolone lupus nephritis lupus Unit RTX

…Objectives Systemic Lupus Erythematosus (SLE) is an autoimmune disease driven by B-cell dysregulation. …

PO:06:165 Immunoglobulin M to oxidation-specific epitope in patients with systemic lupus erythematosus

lupusscimed · abstract · 2026-03-01 · 19 matching annotations

96.6%

systemic lupus erythematosus SLE rheumatoid arthritis RA ApoB100 SLEDAI P1-peptide mimotope

…ular risk, whereas impaired IgM production has been reported in systemic lupus erythematosus (SLE).Methods Serum samples from 137 SLE patients, 135 rheumato…

PO:09:247 Anifrolumab in systemic lupus erythematosus with renal involvement: national multicenter registry in clinical practice

lupusscimed · abstract · 2026-03-01 · 19 matching annotations

98.6%

SLE mycophenolate mofetil SLE-DAS voclosporin tacrolimus belimumab methotrexate azathioprine hidradenitis suppurativa prednisone+3 more

…hods Observational multicenter study of patients diagnosed with SLE (EULAR/ACR 2019 criteria), treated with ANI who presented renal…

PO:10:269 Analysis of a monocentric case series of patients with systemic lupus erythematosus treated with belimumab for more than 10 years

lupusscimed · abstract · 2026-03-01 · 19 matching annotations

99.0%

SLE prednisone hydroxychloroquine BEL RWE SLEDAI-2K Lupus

…ars, analyzing safety and efficacy parameters.Results Among 277 SLE patients in follow-up, 7 were treated with BEL for more than 10…

PO:11:300 Evaluating DORIS remission attainment with anifrolumab in immunosuppressant- and biologic-naïve patients with SLE: design of SUNFLOWER, a phase 3b prospective study

lupusscimed · abstract · 2026-03-01 · 19 matching annotations

98.8%

SLE anifrolumab DORIS AstraZeneca Avalere Health SUNFLOWER

…llowing subcutaneous anifrolumab initiation among patients with SLE who are naïve to conventional immunosuppressants/other biologic…

PO:13:350 Perceptions of live-online fatigue management programmes versus standard care in people with systemic lupus erythematosus: preliminary findings from the FLIP study

lupusscimed · abstract · 2026-03-01 · 19 matching annotations

98.3%

SLE Lupus FMP 7W FMP Abstarct PO FMPs

…l for fatigue management than standard care. People living with SLE in the UK have a preference for live-online group FMPs than sta…

PT1:02 Mitochondrial expansion and interferon-driven bioenergetic reprogramming define CD4+ T cell dysfunction in systemic lupus erythematosus

lupusscimed · abstract · 2026-03-01 · 19 matching annotations

99.5%

SLE IFN-alpha IFN-I

…FN-driven metabolic reprogramming of CD4+ T cells contribute to SLE pathogenesis and highlight bioenergetic checkpoints as rational…

PT4:07 Anifrolumab as rescue therapy in life-threatening, infection-complicated SLE: a biomarker-guided case beyond trial criteria

lupusscimed · abstract · 2026-03-01 · 19 matching annotations

98.2%

Anifrolumab rituximab SLE systemic lupus erythematosus cyclophosphamide pulmonary/mesenteric vasculitis

…ling is a central driver of systemic lupus erythematosus (SLE). Anifrolumab, an anti-IFNAR1 monoclonal antibody, improves outcomes in moder…

Effect of a regional guideline-education initiative on dual antiplatelet therapy use in minor non-cardioembolic stroke: a pre–post analysis from the Shanghai Stroke Service System

svnbmj · abstract · 2026-02-12 · 19 matching annotations

99.0%

NIH Stroke Scale aspirin clopidogrel Shanghai Stroke Service System 4S DAPT minor non-cardioembolic ischaemic stroke Dual antiplatelet therapy acute minor ischaemic stroke high-risk transient ischaemic attack

…. Consecutive adult patients with acute minor ischaemic stroke (National Institutes of Health Stroke Scale≤3) or high-risk TIA (ABCD 2 score ≥4) between 2015 and 2021 wer…

Metformin and incidence of age-related macular degeneration in people with diabetes: a population-based 5-year case-control study

bmjophth · abstract · 2026-02-02 · 19 matching annotations

99.2%

metformin diabetes diabetic retinopathy age-related macular degeneration AMD

…dings remained after adjusting for important confounders. Given metformin’s anti-ageing therapeutic effects, the reduction in risk is pla…

COPD and vitamin K antagonism: a cohort study of 1-year all-cause mortality and risk of hospitalisation due to a severe exacerbation

bmjresp · abstract · 2026-01-27 · 19 matching annotations

96.6%

Chronic obstructive pulmonary disease COPD atrial fibrillation or flutter VKA vitamin K AE-COPD DOAC vitamin K-dependent VKAs

…have a lung-protective effect, though the mechanism is unknown. Chronic obstructive pulmonary disease (COPD) patients treated with vitamin K antagonists (VKAs) may l…

157 Evaluation of the prescribing of prednisolone, in the management of post surgical pericardial effusion

bmjpo · abstract · 2026-01-26 · 19 matching annotations

99.1%

Prednisolone Pericardial effusion

…cardial effusion or suffered haemodynamic compromise.Conclusion Prednisolone 2mg/kg for three days is the most prescribed course for pericar…